lu
al
sought
determin
rel
safeti
efficaci
ceftazidim
amikacin
deliv
either
aerosol
iv
adult
vap
due
pseudomona
aeruginosa
patient
screen
exclud
random
patient
exclud
analysi
patient
exclud
found
bacterem
diagnosi
base
quantit
cultur
lavag
specimen
patient
randomli
assign
aerosol
treatment
receiv
ceftazidim
mgkg
time
daili
day
singl
administr
amikacin
mgkg
daili
day
control
group
patient
given
ceftazidim
mgkg
minut
follow
continu
infus
mgkg
per
day
day
plu
amikacin
mgkg
daili
day
consist
complex
patient
studi
author
manag
analysi
outcom
similarli
complex
overal
howev
signific
differ
detect
treatment
group
clinic
success
achiev
aerosol
group
iv
group
improv
lung
aerat
determin
ct
scan
also
significantli
differ
treatment
arm
bacteri
erad
howev
occur
often
rapidli
aerosol
group
elev
minimum
inhibitori
concentr
isol
intermedi
resist
rang
therapi
occur
patient
assign
receiv
iv
therapi
overal
therapi
gener
well
toler
howev
advers
event
occur
relat
obstruct
respiratori
filter
one
result
nonfat
cardiorespiratori
arrest
rattanaumpawan
et
al
bangkok
examin
whether
addit
nebul
colistimeth
iv
antibiot
chosen
discret
treat
physician
improv
outcom
patient
vap
caus
varieti
gramneg
bacteria
one
hundr
adult
random
receiv
addit
system
therapi
normal
salin
colistimeth
equival
mg
colistin
base
nebul
everi
hour
durat
therapi
left
discret
clinician
isol
suscept
colistin
infect
caus
multidrugresist
acinetobact
baumanii
p
aeruginosa
treatment
well
toler
group
incid
favor
clinic
outcom
group
given
nebul
colistimeth
control
group
also
signific
differ
favor
outcom
treatment
arm
among
patient
p
aeruginosa
infect
vs
p
baumanii
infect
vs
p
favor
microbiolog
outcom
contrast
observ
recipi
nebul
colistimeth
p
control
group
retrospect
casecontrol
studi
koferidi
et
al
compar
patient
vap
due
multidrugresist
gramneg
pathogen
receiv
colistin
iv
aerosol
match
patient
receiv
iv
colistin
alon
infect
due
baumanii
klebsiella
pneumonia
p
aeruginosa
isol
suscept
colistin
clinic
success
cure
improv
observ
iv
alon
group
p
assign
iv
plu
aerosol
colistin
mortal
rate
still
intens
care
unit
group
p
respect
bacteri
erad
rate
significantli
differ
treatment
group
deriv
use
conclus
overal
result
studi
togeth
difficult
differ
design
etiolog
pathogen
although
popul
studi
lu
et
al
homogen
limit
patient
p
aeruginosa
infect
sampl
size
small
despit
conduct
month
multipl
center
patient
treatment
complex
lack
inform
parenter
therapi
make
come
firm
conclus
difficult
prospect
random
trial
rattanaumpawan
et
al
instead
compar
iv
nebul
antibiot
therapi
attempt
assess
impact
ad
latter
former
studi
includ
infect
due
multidrugresist
organ
addit
p
aeruginosa
baumanii
major
pathogen
studi
clinic
benefit
addit
nebul
iv
colistimeth
observ
overal
individu
either
pathogen
final
match
control
studi
baumanii
account
slightli
threefourth
infect
signific
benefit
detect
addit
aerosol
iv
colistin
may
reason
conclud
highli
select
group
adult
nonbacterem
vap
due
p
aeruginosa
may
possibl
avoid
iv
therapi
administr
antibiot
combin
nebul
alon
addit
aerosol
iv
colistimeth
howev
appear
improv
clinic
outcom
patient
pneumonia
due
gramneg
pathogen
antibiot
administr
aerosol
howev
may
rapidli
lead
bacteri
erad
although
may
artifact
result
antibiot
carryov
cultur
seen
studi
may
reduc
likelihood
emerg
drug
resist
therapi
clinician
must
awar
import
risk
associ
aerosol
administr
least
respiratori
filter
potenti
studi
lu
et
al
seriou
advers
effect
jansen
rr
wieringa
j
koekkoek
sm
et
al
frequent
detect
respiratori
virus
without
symptom
toward
defin
clinic
relev
cutoff
valu
j
clin
microbiol
jansen
et
al
perform
prospect
casecontrol
studi
young
children
winter
season
evalu
rel
preval
concentr
respiratori
virus
rv
nasal
wash
specimen
individu
case
without
control
symptom
polymeras
chain
reaction
detect
nucleic
acid
least
rv
case
also
control
least
rv
detect
control
infant
year
age
frequent
detect
rv
case
respiratori
syncyti
viru
rsv
rhinoviru
control
rhinoviru
human
coronaviru
viral
load
lower
asymptomat
children
symptomat
children
potenti
explan
find
includ
presenc
control
subclin
infect
postinfecti
shed
detect
viral
incub
period
last
appear
case
howev
although
respiratori
symptom
develop
week
test
among
control
rv
detect
also
true
p
without
detect
rv
although
studi
indic
identif
rv
young
children
must
view
caution
lost
although
rhinoviru
frequent
detect
asymptomat
children
rsv
result
consist
previou
studi
find
suggest
detect
paramyxoviru
may
consid
diagnost
diseas
